Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses
Authors
Wang, DanMou, Haiwei
Li, Shaoyong
Li, Yingxiang
Hough, Soren
Tran, Karen
Li, Jia
Yin, Hao
Anderson, Daniel G.
Sontheimer, Erik J.
Weng, Zhiping
Gao, Guangping
Xue, Wen
UMass Chan Affiliations
Gene Therapy CenterRNA Therapeutics Institute
Program in Molecular Medicine
Program in Bioinformatics and Integrative Biology
Document Type
Journal ArticlePublication Date
2015-07-01Keywords
Biochemistry, Biophysics, and Structural BiologyBioinformatics
Computational Biology
Immunity
Immunoprophylaxis and Therapy
Integrative Biology
Systems Biology
Metadata
Show full item recordAbstract
CRISPR/Cas9 derived from the bacterial adaptive immunity pathway is a powerful tool for genome editing, but the safety profiles of in vivo delivered Cas9 (including host immune responses to the bacterial Cas9 protein) have not been comprehensively investigated in model organisms. Nonalcoholic steatohepatitis (NASH) is a prevalent human liver disease characterized by excessive fat accumulation in the liver. In this study, we used adenovirus (Ad) vector to deliver a Streptococcus pyogenes-derived Cas9 system (SpCas9) targeting Pten, a gene involved in NASH and a negative regulator of the PI3K-AKT pathway, in mouse liver. We found that the Ad vector mediated efficient Pten gene editing even in the presence of typical Ad vector-associated immunotoxicity in the liver. Four months after vector infusion, mice receiving the Pten gene-editing Ad vector showed massive hepatomegaly and features of NASH, consistent with the phenotypes following Cre-loxP-induced Pten deficiency in mouse liver. We also detected induction of humoral immunity against SpCas9 and the potential presence of an SpCas9-specific cellular immune response. Our findings provide a strategy to model human liver diseases in mice and highlight the importance considering Cas9-specific immune responses in future translational studies involving in vivo delivery of CRISPR/Cas9.Source
Hum Gene Ther. 2015 Jul;26(7):432-42. doi: 10.1089/hum.2015.087. Link to article on publisher's siteDOI
10.1089/hum.2015.087Permanent Link to this Item
http://hdl.handle.net/20.500.14038/25937PubMed ID
26086867Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1089/hum.2015.087